Furthermore, polymorphisms in genes encoding members of both CXCL8:CXCR1/2 and the VEGF:VEGFR signaling axes are linked to morbidity and response to anti-VEGF therapy in angiogenic diseases, including AMD and cancers [9, 11, 14, 63–65]. This evidence concerns the gene CXCL8 and cancer.